Treatments Available for High Risk Smoldering Myeloma Patients
Join with us to learn the answers to the following questions with myeloma specialist Dr. Manasanch.
- What constitutes high-risk smoldering myeloma?
- What treatments are available to these patients?
- What are the risks of treating too early?
- Do you recommend clinical trials to all of your high risk SMM patients?
- Will the future always be watch and wait?
Audrey introduces the agenda of the event and featured speaker Elisabet E. Manasanch, M.D.
Dr. Manasanch talks about treatments for Smoldering Myeloma.
Type your questions in the chat and we will answer them!
Audrey Burton-Bethke
Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.
Elisabet Manasanch, MD
Dr. Manasanch specializes in the treatment of patients with multiple myeloma. Furthermore, she focuses on translational research of the precursor stages of myeloma and early disease management through groundbreaking immunotherapy-focused clinical trials.